19 February 2020 07:00 GMT
�
�
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
�
AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demar�, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demar� purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of �73.13 per Share.
�
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
�
| 1 � | Details of the person discharging managerial responsibilities / person closely associated � | |||||
| a) � | Name � � | Michel Demar� | ||||
| 2 � | Reason for the notification � | |||||
| a) � | Position/status � � | Non-Executive Director | ||||
| b) � | Initial notification /Amendment � � | Initial notification | ||||
| 3 � | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor � | |||||
| a) � | Name � � | AstraZeneca PLC | ||||
| b) � | LEI � � | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 � | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted � � | |||||
| a) � | Description of the financial instrument, type of instrument � Identification code � � | Ordinary Shares of US$0.25 each in AstraZeneca PLC � � GB0009895292 � | ||||
| b) � | Nature of the transaction � � | Share purchase | ||||
| c) � | Price(s) and volume(s) � � | �
� � | ||||
| d) � | Aggregated information � � - Aggregated volume � � - Price � � | Not applicable - single transaction � | ||||
| e) � | Date of the transaction � � | 17 February 2020 | ||||
| f) � | Place of the transaction � � | XLON | ||||
�
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com�and follow us on Twitter @AstraZeneca.
�
| � Media Relations | � | � |
| Gonzalo Vi�a | � | +44 203 749 5916 |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Jennifer Hursit | Other | +44 203�749 5762 |
| Christina Malmberg H�gerstrand | Sweden | +46 8�552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| � | � | � |
| Investor Relations | � | � |
| Thomas Kudsk Larsen | � | +44 203 749 5712 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals (cardiovascular; metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (respiratory; renal) | +44 203 749 5716 |
| Josie Afolabi | Other medicines | +44 203 749 5631 |
| Craig Marks | Finance, fixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate access, retail investors | +44 203 749 5824 |
| US toll-free | � | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC